Retatrutide Phase 3 results: 20.8% average weight loss in adults with type 2 diabetes

What the source reports

Eli Lilly has released detailed results from TRIUMPH-2, an 80-week Phase 3 trial of retatrutide in adults who had type 2 diabetes and either obesity or overweight. The headline result was first announced in July; the new release adds dose-by-dose weight, A1C, response and adverse-event figures and coincides with presentation at the European Association for the Study of Diabetes meeting.

At the 12 mg dose, participants lost an estimated average of 20.8% of their starting weight—49.6 lb or 22.5 kg—from an average baseline weight of 234.6 lb. The placebo group lost 4.0%, or 9.3 lb, over the same period. Retatrutide remains investigational and cannot currently be prescribed or legally marketed as an approved treatment.

This is a more specific update than the topline result covered in our July news roundup. The added detail helps show the dose response and the trade-off between efficacy and tolerability, although full regulatory review is still ahead.

How TRIUMPH-2 was designed

TRIUMPH-2 randomised 1,152 adults equally to once-weekly retatrutide at a target dose of 4 mg, 9 mg or 12 mg, or to placebo. Participants had type 2 diabetes and obesity or overweight. Treatment began at 2 mg and was increased in four-week steps towards the assigned target dose.

The trial was double-blind and placebo-controlled. Its main 80-week analysis assessed change in body weight and A1C, the blood test used to estimate average glucose over the preceding two to three months.

The reported headline numbers use an efficacy estimand. In plain language, this estimates the treatment effect if participants had remained on their assigned intervention, allowing temporary dose changes, without prohibited weight-management treatment or glycaemic rescue therapy for the glucose endpoints. It is not the same as simply averaging every participant regardless of stopping or switching.

Weight loss increased with dose

Average weight change at week 80 was 12.7% with 4 mg, 19.1% with 9 mg and 20.8% with 12 mg, compared with 4.0% for placebo. At the highest dose, 67.0% of participants achieved at least 15% weight loss, 52.0% achieved at least 20%, and 34.9% achieved at least 25% under the reported analysis.

Lilly also reported that 59.5% of the 12 mg group no longer met the BMI threshold for obesity at the end of the study. That is a group-level category change, not proof that obesity-related risk disappeared, and BMI alone does not describe body composition, fitness or an individual's overall health.

Participants who began with a BMI of at least 35 lost an estimated average of 23.4% on 12 mg. Subgroup results can be useful, but they should not be treated as a prediction of what any individual would lose.

Blood-glucose results were substantial too

Average A1C fell by 1.4 percentage points with 4 mg, 1.6 points with 9 mg and 1.5 points with 12 mg, versus 0.2 points with placebo, from an average baseline of 7.7%.

Up to 40.0% of participants reached an A1C below 5.7%, the laboratory threshold normally used to define the non-diabetes range, compared with 4.4% on placebo. Reaching that test threshold during a trial does not mean type 2 diabetes has been permanently cured, particularly while treatment continues.

The study also reported improvements in triglycerides, non-HDL cholesterol, systolic blood pressure, waist circumference and high-sensitivity C-reactive protein. These are risk markers; TRIUMPH-2 was not designed to prove that retatrutide prevents heart attacks, strokes or deaths.

The side-effect figures matter

Gastrointestinal events were the most frequently reported problems. Diarrhoea affected 27.4%, 33.5% and 33.6% of the 4 mg, 9 mg and 12 mg groups respectively, compared with 13.2% on placebo. Nausea occurred in 13.7%, 20.8% and 28.0%, versus 8.0% with placebo; vomiting occurred in 5.5%, 10.2% and 15.7%, versus 4.2%.

The company described most events as mild to moderate and said most resolved during treatment. Discontinuation because of adverse events was 3.8% with 4 mg, 11.6% with 9 mg and 7.7% with 12 mg, compared with 4.9% on placebo. The non-linear pattern is a reminder that a single percentage cannot summarise tolerability.

Dysaesthesia—altered or unusual skin sensation—was reported in 4.5%, 5.6% and 7.3% of the ascending-dose groups versus 0.7% with placebo. Regulators will assess the complete adverse-event dataset rather than only the selected results in a company announcement.

Why it is called a triple agonist

Retatrutide is a single molecule designed to activate receptors for GIP, GLP-1 and glucagon. Tirzepatide targets GIP and GLP-1, while semaglutide targets GLP-1. Adding glucagon-receptor activity is intended to influence energy balance alongside appetite and glucose regulation.

That mechanism makes retatrutide part of the next generation of incretin-based research, but a more complex mechanism is not automatically better for every person. Benefits, adverse effects, dose, treatment persistence, medical history, access and long-term outcomes all matter.

Approval has not happened

Lilly says it plans to submit a Biologics License Application to the US Food and Drug Administration in the first quarter of 2027. A planned application is not an approval date, and a regulator may request further analyses or information before reaching a decision.

Products advertised online as retatrutide are not an approved version of this investigational medicine. Trial participants receive a defined product under research oversight; that is fundamentally different from purchasing an unverified substance described as a research peptide.

What remains uncertain

Longer follow-up is needed to understand durability, uncommon harms and what happens after treatment stops. Cardiovascular and kidney outcome studies are also important because changes in risk markers do not establish fewer clinical events.

The trial compared retatrutide with placebo rather than semaglutide, tirzepatide or another active obesity medicine. Percentages from separate trials should not be arranged as a league table because populations, durations, doses, support and statistical methods differ.

The strongest conclusion is therefore narrow but important: in this controlled Phase 3 trial, retatrutide produced substantial average reductions in weight and A1C in adults with type 2 diabetes and obesity or overweight, with frequent gastrointestinal effects and a regulatory decision still to come.

Bottom line

TRIUMPH-2 strengthens the evidence that a GIP, GLP-1 and glucagon triple agonist can address weight and glucose together in a population that often loses less weight in obesity trials than participants without diabetes.

It does not make retatrutide an available medicine. The detailed efficacy and side-effect results now move the conversation towards regulatory scrutiny, longer-term outcomes and whether the benefits remain acceptable outside a tightly managed trial.